The benefits of sacubitril–valsartan in patients with acute myocardial infarction: a systematic review and meta‐analysis

Aims We aimed to investigate whether sacubitril–valsartan could further improve the prognosis, cardiac function, and left ventricular (LV) remodelling in patients following acute myocardial infarction (AMI). Methods and results We searched the PubMed, Embase, Cochrane Library, and China National Kno...

Full description

Saved in:
Bibliographic Details
Published in:ESC Heart Failure 2021-12, Vol.8 (6), p.4852-4862
Main Authors: Xiong, Bo, Nie, Dan, Qian, Jun, Yao, Yuanqing, Yang, Gang, Rong, Shunkang, Zhu, Que, Du, Yun, Jiang, Yonghong, Huang, Jing
Format: Article
Language:English
Subjects:
Acute myocardial infarction
Angioplasty
Angiotensin receptor blockers
Angiotensin‐converting enzyme inhibitors
Bias
Cardiovascular disease
Confidence intervals
Ejection fraction
Enzymes
Heart attacks
Heart failure
Hospitalization
Hyperkalemia
Hypotension
Meta-analysis
Mortality
Original
Peptides
Sacubitril–valsartan
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Aims We aimed to investigate whether sacubitril–valsartan could further improve the prognosis, cardiac function, and left ventricular (LV) remodelling in patients following acute myocardial infarction (AMI). Methods and results We searched the PubMed, Embase, Cochrane Library, and China National Knowledge Infrastructure (CNKI) from inception to 10 May 2021 to identify potential articles. Randomized controlled trials (RCTs) meeting the inclusion criteria were included and analysed. Thirteen RCTs, covering 1358 patients, were analysed. Compared with angiotensin‐converting enzyme inhibitors (ACEI)/angiotensin receptor blockers (ARB), sacubitril–valsartan did not significantly reduced the cardiovascular mortality [risk ratio (RR) 0.65, 95% confidence interval (CI) 0.22 to 1.93, P = 0.434] and the rate of myocardial reinfarction (RR 0.65, 95% CI 0.29 to 1.46, P = 0.295) of patients following AMI, but the rate of hospitalization for heart failure (HF) (RR 0.48, 95% CI 0.35 to 0.66, P 
ISSN:2055-5822
2055-5822
DOI:10.1002/ehf2.13677